Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04057196
Other study ID # Pro00102705
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2, 2020
Est. completion date June 24, 2021

Study information

Verified date July 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study to use Self-system therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).


Description:

The investigator will examine whether delivering the SST intervention will be both feasible and acceptable to study participants. The investigator will also examine whether participation in SST can help alleviate symptoms of depression and distress while helping improve overall functioning in older adults with advanced lung cancer.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 24, 2021
Est. primary completion date May 20, 2021
Accepts healthy volunteers No
Gender All
Age group 65 Years to 100 Years
Eligibility Inclusion Criteria: - Age = 65 years - English-speaking - The patient has a diagnosis of late-stage (III-IV) lung cancer and is living at her/his home. Exclusion Criteria: - Unable to provide informed consent - Visual or hearing impairments that preclude participation - Serious mental illness

Study Design


Intervention

Behavioral:
Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)
The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.

Locations

Country Name City State
United States Duke University Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Strauman TJ, Eddington KM. Treatment of Depression From a Self-Regulation Perspective: Basic Concepts and Applied Strategies in Self-System Therapy. Cognit Ther Res. 2017 Feb;41(1):1-15. doi: 10.1007/s10608-016-9801-1. Epub 2016 Aug 29. — View Citation

Waters SJ, Strauman TJ, McKee DC, Campbell LC, Shelby RA, Dixon KE, Fras AM, Keefe FJ. Self-system therapy for distress associated with persistent low back pain: A randomized clinical trial. Psychother Res. 2016 Jul;26(4):472-83. doi: 10.1080/10503307.2015.1040485. Epub 2015 Jun 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients That Complete SST Treatment Sessions Completion of at least 85% of SST treatment sessions across a 12-week period. up to week 12
Primary Patient Satisfaction With Treatment The Client Satisfaction Questionnaire (CSQ-8), which assesses treatment credibility (pre-treatment) and effectiveness of/satisfaction with services (post-treatment). An overall score is calculated by summing the respondent's rating (item rating) score for each scale item. For the CSQ-8 version, scores therefore range from 8 to 32, with higher values indicating higher satisfaction. End of study, week 12
Secondary General Distress as Measured by the CORE-10 (Clinical Outcomes in Routine Evaluation 10) at Baseline The CORE-10 measure will be used for rating general distress. The measure comprises ten questions about how participants have been feeling over the past week. Scores range from 0-40, with higher scores indicating greater distress. Baseline
Secondary General Distress as Measured by the CORE-10 at 12 Weeks The CORE-10 measure will be used for rating general distress. The measure comprises ten questions about how participants have been feeling over the past week. Scores range from 0-40, with higher scores indicating greater distress. 12 weeks
Secondary General Distress as Measured by the CORE-10 at 1-month Follow-up The CORE-10 measure will be used for rating general distress. The measure comprises ten questions about how participants have been feeling over the past week. Scores range from 0-40, with higher scores indicating greater distress. 1-month follow-up, up to 4 months
Secondary Depression as Measured by the Beck Depression Inventory (BDI-II) at Baseline Depression will be measured using the Beck Depression Inventory (BDI-II). The measure has 21 items. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The total score ranges from 0 to 63, where higher scores indicate greater depression. Baseline
Secondary Depression as Measured by the Beck Depression Inventory (BDI-II) at 12 Weeks Depression will be measured using the Beck Depression Inventory (BDI-II). The measure has 21 items. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The total score ranges from 0 to 63, where higher scores indicate greater depression. 12 weeks
Secondary Depression as Measured by the Beck Depression Inventory (BDI-II) at 1-month Follow-up Depression will be measured using the Beck Depression Inventory (BDI-II). The measure has 21 items. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The total score ranges from 0 to 63, where higher scores indicate greater depression. 1-month follow-up, up to 4 months
Secondary Functioning as Measured by the Functional Assessment of Cancer Therapy- Lung (FACT-L) Functioning will be measured using the Functional Assessment of Cancer Therapy- Lung (FACT-L). The FACT-L is a 36-item measure, each item with a five-point scale from 0 (not at all) to 4 (very much), measuring overall quality of life (QOL) across five dimensions that are summed together to derive a total score. The total score range is from 0-136. The higher the score, the better the QOL. Baseline, 12 weeks, 1 month follow-up (up to 4 months)
Secondary Number of Participants With Participant-reported Mobility Indices Available Mobility indices will include participant report of difficulty walking across a room without help from another person or equipment (none, a little vs some, a lot, unable), difficulty walking two to three blocks without help from another person or equipment (none, a little vs some, a lot, unable), and use of assistive device (yes vs no). Baseline, 12 weeks, 1 month follow-up (up to 4 months)
Secondary Number of Participants With Physical Activity Scale for the Elderly (PASE) Scores Available Physical Activity will be measured using the Physical Activity Scale for the Elderly (PASE)The instrument is comprised of self-reported occupational, household and leisure activities items over a one-week period. PASE scores are calculated from weights and frequency values for each of 12 types of activity. Baseline, 12 weeks, 1 month follow-up (up to 4 months)
Secondary Number of Participants With Computerized Selves Questionnaire (CSQ) Responses Available at Baseline Self-Discrepancy will be measured using the Computerized Selves Questionnaire (CSQ). The CSQ is a computer-based version of the original self-discrepancy questionnaire used by Higgins and colleagues (1986) in which a person is asked to produce a list of eight personal attributes that s/he would ideally like to possess and eight attributes s/he feels s/he ought to possess. To score, qualities in the actual self column are compared with those in the ought self column. Baseline
Secondary Number of Participants With Regulatory Focus Questionnaire (RFQ) Responses Available at Baseline Self-Regulatory Orientation will be measured using the Regulatory Focus Questionnaire (RFQ).The measure has 11 items using 5-point scales, along two sub scales measuring the extent to which an individual believes s/he has been successful in attaining promotion or prevention goals. Six questions quantify Promotion and five questions quantify Prevention the promotion sums must be divided by 6, and the prevention sums must be divided by 5 in order to place scores for both orientations on the same 1-5 scale. Baseline
Secondary Treatment Session Fidelity as Measured by Number of Participants Who Were Taught All Skills. Trained raters will listen to audio recordings of treatment sessions and use a pre-defined checklist of session content and strategies of the treatment to indicate if session coping skills were taught (yes/no) coded as 1 for yes and 0 for no. Higher scores indicate greater session fidelity. End of study, week 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03668496 - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Phase 3
Active, not recruiting NCT03322072 - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating N/A
Recruiting NCT05497973 - Psychosocial eHealth in Advanced Lung Cancer N/A
Recruiting NCT06076005 - Lung Cancer ID (Identity) Study
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Completed NCT03529851 - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients N/A
Completed NCT03558165 - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed NCT03076164 - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Phase 1/Phase 2
Not yet recruiting NCT03153358 - Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation Phase 2
Recruiting NCT04595734 - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting NCT04519983 - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs Phase 2
Not yet recruiting NCT05701384 - Lazertinib 160mg in EGFR T790M NSCLC Phase 2
Withdrawn NCT03409341 - Personalizing Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT03728361 - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Phase 2
Not yet recruiting NCT06024941 - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer Phase 2
Recruiting NCT04669223 - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion N/A
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Recruiting NCT06000358 - The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer N/A